Abstract
Objective:
This study aims to identify factors influencing successful recanalization following endovascular intervention for non-acute basilar artery occlusion (NABAO).
Background:
Endovascular treatment (EVT) is a feasible approach for treating non-acute basilar artery occlusion, but it presents significant technical challenges due to the lack of standardized treatment protocols. Therefore, identifying patients most likely to benefit is critical to minimizing procedural risks.
Methods:
A retrospective analysis was conducted on 115 patients with NABAO treated via EVT. Factors associated with successful recanalization, including clinical symptoms, demographic characteristics, procedural outcomes, and imaging findings, were analyzed using multivariate analysis. A scoring system was developed based on independent predictors.
Results:
Successful recanalization (defined as modified Thrombolysis in Cerebral Infarction [mTICI] ≥2b) was achieved in 81.7% (94/115) of cases. Multivariate analysis revealed that occlusion duration >3 months (odds ratio [OR]: 0.187, 95% confidence interval [CI]: 0.051–0.688, p = 0.012), blunt-shaped occlusion ends (OR: 0.236, 95% CI: 0.072–0.777, p = 0.018), occlusion length > 30 mm (OR: 0.144, 95% CI: 0.031–0.669, p = 0.013), and insufficient or absent distal compensation (OR: 0.25, 95% CI: 0.075–0.835, p = 0.024) were independent predictors of reduced technical success. The receiver operating characteristic (ROC) curve index for the scoring system, based on these independent predictors, was 0.817 (95% CI: 0.698–0.936, p < 0.001), with a sensitivity of 71.4% and a specificity of 85.4% at a cutoff of 2.5 points.
Conclusion:
Longer occlusion duration (>3 months), blunt-shaped occlusion ends, occlusion length > 30 mm, and insufficient distal collateral compensation are independent negative predictors for successful recanalization in patients with NABAO treated via EVT. The proposed scoring system can help screen patients suitable for treatment and optimize treatment strategies, but further validation in prospective cohorts is needed.
1 Introduction
Stroke remains a leading cause of disability and mortality worldwide, with acute ischemic stroke (AIS) accounting for nearly 80% of all cases (1–3). Early intervention to restore blood flow and salvage the ischemic penumbra is critical for improving outcomes in AIS (4, 5). The current gold-standard treatments for early recanalization include intravenous tissue plasminogen activator (rt-PA) thrombolysis and mechanical thrombectomy (6, 7). However, the narrow therapeutic time window limits the number of patients who are eligible for these interventions, leaving a substantial proportion untreated (8).
The efficacy of endovascular treatment (EVT) in acute posterior circulation large vessel occlusion has been well established. A recent meta-analysis revealed that for patients with acute vertebrobasilar artery occlusion presenting moderate to severe symptoms, EVT significantly increases the likelihood of achieving favorable functional outcomes by approximately 2.5-fold and markedly reduces overall disability and mortality rates (9). For adult patients with basilar artery occlusion (BAO)-related acute ischemic stroke presenting within 24 h from last known well, current guidelines recommend EVT combined with best medical therapy (BMT) over BMT alone, with this recommendation applies only to patients with a National Institutes of Health Stroke Scale (NIHSS) score of 10 or higher (10). However, for patients with BAO who fall outside the recommended time window for intervention, no consensus exists regarding optimal treatment strategies. Current international guidelines continue to recommend antiplatelet therapy, statins, lifestyle modification, and aggressive management of vascular risk factors, yet clinical outcomes remain suboptimal with these approaches (11, 12). Emerging evidence from single-center studies suggests that EVT for non-acute basilar artery occlusion (NABAO) may be feasible, offering potential benefits in restoring perfusion and improving clinical prognosis (13). Nonetheless, the procedural risks remain high, and success rates are inconsistent, primarily due to heterogeneous occlusion characteristics (e.g., chronicity, morphology) and the absence of validated selection criteria. Unlike Acute Basilar Artery Occlusion (ABAO), where thrombus composition and timing dominate decision-making, NABAO requires distinct predictors to balance procedural risks (e.g., vessel dissection, hemorrhage) against potential benefits.
Current literature on NABAO EVT is limited to small retrospective cohorts (14), with no consensus on which patients are optimal candidates. Key questions remain unanswered: How do occlusion duration, morphology, and collateral status interact to influence recanalization success? Can a standardized scoring system guide clinicians in selecting patients most likely to benefit from EVT?
A major challenge of NABAO EVT lies in identifying patients who are most likely to benefit from EVT and who have a high likelihood of successful recanalization. This study presents a retrospective analysis of NABAO treated with endovascular recanalization, aiming to identify predictors of successful outcomes and to develop a scoring system to aid in patient selection for intervention.
2 Methods
We conducted a retrospective, multi-center study of NABAO recanalization treatment from January 2019 to February 2024. Basilar artery occlusion was evaluated using computed tomography angiography (CTA) and confirmed by digital subtraction angiography (DSA). Non-acute basilar artery occlusion was defined as occlusion diagnosed more than 24 h after symptom onset (14). All patients underwent endovascular intervention following the signing of informed surgical consent.
2.1 Inclusion criteria
(1) Age > 18 years.
(2) Duration of basilar artery occlusion >24 h.
(3) Basilar artery occlusion confirmed by DSA.
(4) Consent for endovascular recanalization provided by the patient or their family members, following detailed explanation of the procedure and risks (14).
2.2 Exclusion criteria
(1) Patients diagnosed with NABAO via DSA but who declined endovascular intervention, either personally or via family members.
(2) Severe cardiac insufficiency or significantly impaired liver and kidney function, rendering the patient unfit for surgery.
(3) Patients with cachexia, untreated malignant tumors, or an expected life expectancy of less than 2 years.
(4) Patients with non-atherosclerotic causes of occlusion, including arterial dissection, cardiogenic embolism, vasculitis, history of radiotherapy, or congenital vascular malformations.
(5) History of cerebral hemorrhage.
(6) Patients with a high risk of bleeding or contraindications to antiplatelet therapy.
(7) Recent gastrointestinal bleeding, major surgical procedures, or fever within the past month that had not been effectively controlled.
(8) Patients with active sepsis where blood cultures remained positive (14).
2.3 Interventional techniques
2.3.1 Preoperative preparation
All patients were placed on dual antiplatelet therapy (DAPT) for 5 days before the procedure. This regimen included aspirin (100 mg daily) and clopidogrel (75 mg daily) (15). Additionally, patients received 40 mg of atorvastatin daily to stabilize atherosclerotic plaques and lower lipid levels.
2.3.2 Surgical procedure
All procedures were performed under general anesthesia by experienced neurointerventional surgeons. Each surgeon had at least 5 years of experience in neurointerventional procedures, including the treatment of chronic occlusions of large intracranial vessels (minimum of 5 cases) or emergency thrombectomy (at least 10 cases). The annual caseload for intracranial stent placements exceeded 10 cases per surgeon in the previous 3 years (16).
During the procedure, an initial dose of 3,000 units of heparin was administered intravenously, with 1,000 additional units given every hour to maintain anticoagulation. A 5F or 6F intermediate catheter was used to access the target vertebral artery. An intracranial microcatheter and neuroguidewire were employed to attempt passage through the occluded segment. If the guidewire failed to cross the occlusion after 30 min of attempts, if the cumulative contrast volume exceeded 300 mL, or if the guidewire penetrated the vessel wall, the procedure was considered a failure of recanalization (17).
If successful, the microcatheter was advanced through the occlusion, and intravascular angiography was performed to confirm that the guidewire was within the true lumen. Subsequently, a 300 cm exchange guidewire was placed, and a 1.5 or 2.0 mm intracranial balloon was used for pre-dilation of the occlusion. If there was no elastic recoil or vascular dissection at the stenosis site, stenting was not required. However, if recoil or dissection occurred, an appropriately sized balloon-expandable or self-expanding stent was deployed. If the stent did not fully expand, post-dilation was performed. A recanalization was deemed successful if the final blood flow reached a modified Thrombolysis in Cerebral Infarction (mTICI) grade of 2b or higher (18).
2.4 Postoperative management
Nimodipine was administered postoperatively to prevent vasospasm, and blood pressure was strictly maintained between 110–120/60–80 mmHg. DAPT was continued for 3 to 6 months after the procedure, followed by single antiplatelet therapy. Long-term lipid-lowering therapy with statins was prescribed to maintain stable cholesterol levels.
2.5 Imaging assessment
Surgical outcomes and lesion imaging characteristics were independently assessed by two neurointerventional specialists. In cases of disagreement, a third independent expert reviewed the images to reach a consensus. The presence of contrast filling at the distal end of the occlusion was defined as a stump, which was classified as either conical or blunt. Occlusion length was measured on lateral DSA images, from the point of occlusion to the distal reconstitution site, excluding curvature in the vessel. Occlusions were categorized as ≤30 mm or > 30 mm. If the distal end was not visible, the occlusion length was considered >30 mm. On lateral DSA, two lines were drawn from the confluence of the vertebral arteries to the basilar artery and from the established access point to the vertebral artery, with the angle formed between these lines recorded as the vertebro-basilar artery (VA-BA) non-planar angle (19).
2.6 Statistical analysis
Statistical analyses were conducted using IBM SPSS Statistics version 25.0 (SPSS Inc., Chicago, IL, USA). Categorical variables were presented as counts and percentages, and compared using the chi-square test, continuity-corrected chi-square test, or Fisher’s exact test. Continuous variables were tested for normality using the Kolmogorov–Smirnov test. Data following a normal distribution were expressed as mean ± standard deviation (SD) and compared using the independent t-test, while non-normally distributed data were reported as median and interquartile range (IQR) and compared using the Mann–Whitney U test. A p-value ≤0.05 was considered statistically significant.
Logistic regression was performed for variables with p ≤ 0.05 in univariate analysis, adjusted for age and gender. Multivariate logistic regression was then used to identify independent predictors, and scores were assigned based on the coefficients of significant variables. Receiver operating characteristic (ROC) curves were used to evaluate model performance, with the Youden index determining sensitivity and specificity. Area under the curve (AUC) values were interpreted as follows: AUC ≤0.5 (low), 0.7 < AUC ≤0.9 (moderate), and AUC >0.9 (high).
3 Results
A total of 115 patients with symptomatic NABAO underwent endovascular treatment for recanalization. Among the patients, 78 were male (67.2%) and 37 were female (32.2%), with an age range of 41 to 84 years (mean age 63.01 ± 9.47 years). The overall recanalization success rate was 81.7% (94/115). Demographic and lesion characteristics are summarized in Tables 1, 2.
Table 1
| Failure group (N = 21) | Success group (N = 94) | Total (N = 115) | p value | |
|---|---|---|---|---|
| Age (years) | 63.19 ± 7.731 | 62.97 ± 9.848 | 63.01 ± 9.466 | 0.923 |
| Male (%) | 18 (85.7) | 60 (63.8) | 78 (67.8) | 0.052 |
| Hypertension (%) | 15 (71.4) | 73 (77.7) | 88 (75.5) | 0.746 |
| Diabetes mellitus (%) | 6 (28.6) | 34 (36.2) | 40 (34.8) | 0.44 |
| Hyperlipidemia (%) | 7 (33.3) | 31 (33.0) | 38 (33.0) | 0.975 |
| Hyperhomocysteinemia (%) | 7 (33.3) | 27 (28.7) | 34 (29.6) | 0.676 |
| Smoking (%) | 6 (28.6) | 13 (13.7) | 19 (16.5) | 0.187 |
| Coronary artery disease (%) | 5 (23.8) | 11 (11.7) | 16 (13.9) | 0.271 |
| Total Cholesterol mg/dL | 168.47 ± 41.70 | 182.06 ± 50.01 | 179.58 ± 4.72 | 0.249 |
| Creatinine mg/dL | 0.94 (0.80–1.050) | 0.845 (0.67–1.01) | 0.86 (0.70–1.03) | 0.105 |
| Estimated Glomerular Filtration Rate ml/min | 84.87 ± 25.40 | 91.60 ± 30.39 | 90.36 ± 29.55 | 0.348 |
Demographic characteristics.
Estimated glomerular filtration rate, calculated from the diet change in renal disease (MDRD) formula.
Table 2
| Failure group (N = 21) | Success group (N = 94) | Total (N = 115) | p value | |
|---|---|---|---|---|
| Calcification over occluded segment (%) | 3 (14.3) | 9 (9.60) | 12 (10.4) | 0.807 |
| Occlusion stump condition | ||||
| Tapered (%) | 7 (33.3) | 70 (74.5) | 77 (67.00) | < 0.001 |
| Blunt (%) | 14 (66.7) | 24 (25.5) | 38 (33.0) | |
| Angle of basilar artery and vertebral artery >45° (%) | 10 (47.6) | 30 (31.9) | 40 (34.8) | 0.172 |
| Occlusion length > 30 mm (%) | 6 (28.6) | 6 (6.4) | 12 (10.4) | 0.009 |
| Occlusion site | ||||
| BA distal (%) | 4 (19.05) | 12 (12.77) | 16 (13.91) | 0.280 |
| BA mid-end (%) | 8 (38.10) | 22 (23.40) | 30 (26.09) | |
| BA proximal (%) | 9 (42.85) | 60 (63.83) | 69 (60.00) | |
| Good collateral circulation (%) | 9 (42.9) | 62 (66.0) | 71 (61.7) | 0.049 |
| Time from diagnosis of vessel occlusion to endovascular intervention | ||||
| ≤ 3 months | 9 (42.9) | 75 (79.8) | 84 (73.0) | 0.001 |
| > 3 months | 12 (57.1) | 19 (20.2) | 31 (27.0) | |
Lesion characteristics.
3.1 Univariate analysis
Univariate logistic regression analysis was performed to identify factors associated with successful recanalization. The odds ratio (OR) and 95% confidence interval (CI) for blunt-type vessel occlusion were 0.17 (95% CI: 0.060–0.481, p = 0.001), for occlusion length > 30 mm were 0.15 (95% CI: 0.040–0.566, p = 0.005), for absence or insufficiency of collateral circulation were 0.345 (95% CI: 0.128–0.933, p = 0.036), and for time from diagnosis to surgery >3 months were 0.202 (95% CI: 0.07–0.586, p = 0.003). These findings suggest that each of these factors was associated with a lower likelihood of successful recanalization. The results of the univariate analysis are detailed in Table 3.
Table 3
| OR (95% Cl) | p value | |
|---|---|---|
| Hypertension | 0.658 (0.217–1.997) | 0.46 |
| Diabetes mellitus | 0.816 (0.279–2.385) | 0.71 |
| Hyperlipidemia | 1.067 (0.383–2.976) | 0.901 |
| Hyperhomocysteinemia | 1.089 (0.388–3.057) | 0.871 |
| Smoking history | 1.974 (0.599–6.498) | 0.263 |
| Coronary heart disease | 1.281 (0.311–5.288) | 0.732 |
| Total cholesterol | 1.007 (0.996–1.018) | 0.207 |
| Creatinine | 1.056 (0.423–2.632) | 0.908 |
| Estimated Glomerular Filtration Rate | 1.006 (0.989–1.024) | 0.492 |
| Calcification at the occlusion site | 1.529 (0.333–7.012) | 0.585 |
| Blunt | 0.17 (0.060–0.481) | 0.001 |
| Angle of basilar artery and vertebral artery >45° | 1.699 (0.638–4.530) | 0.289 |
| Occlusion length > 30 mm | 0.15 (0.040–0.566) | 0.005 |
| Occlusion site | ||
| BA distal | 1.173 (0.219–6.288) | 0.852 |
| BA mid-end | 1.443 (0.364–5.716) | 0.601 |
| BA proximal | 0.506 (0.166–1.548) | 0.233 |
| Absent or insufficient distal collateral compensation | 0.345 (0.128–0.933) | 0.036 |
| Time from diagnosis of vascular occlusion to surgery >3 months | 0.202 (0.07–0.586) | 0.003 |
Single factor logistic regression analysis of successful factors for intravascular recanalization.
OR, Odds Ratio; CI, Confidence Interval. Bold values indicate statistically significant results (p < 0.05).
3.2 Multivariate analysis
Multivariate logistic regression analysis, adjusted for age and gender, was conducted on variables with p ≤ 0.05 in univariate analysis. These variables included blunt morphology of the occlusion, occlusion length > 30 mm, absence or insufficiency of distal collateral compensation, and time from diagnosis to surgery >3 months. The analysis identified the following as negative predictors of successful recanalization: blunt occlusion morphology (OR: 0.236, 95% CI: 0.072–0.777), occlusion time > 3 months (OR: 0.187, 95% CI: 0.051–0.688), occlusion length > 30 mm (OR: 0.144, 95% CI: 0.031–0.669), and absence or insufficiency of distal collateral compensation (OR: 0.25, 95% CI: 0.075–0.835). These results are shown in Table 4.
Table 4
| Coefficient | OR (95% CI) | p value | |
|---|---|---|---|
| Gender | −0.868 | 0.42 (0.091–1.938) | 0.266 |
| Age | 0.015 | 1.015 (0.948–1.086) | 0.678 |
| Operation time > 3 months | −1.678 | 0.187 (0.051–0.688) | 0.012 |
| Blunt | −1.443 | 0.236 (0.072–0.777) | 0.018 |
| Occlusion length > 30 mm | −1.936 | 0.144 (0.031–0.669) | 0.013 |
| Absent or insufficient distal collateral compensation | −1.385 | 0.25 (0.075–0.835) | 0.024 |
Multivariate logistic regression analysis after adjusting for gender and age.
OR, Odds Ratio; CI, Confidence Interval. Bold values indicate statistically significant results (p < 0.05).
3.3 Basilar artery occlusion scoring system
A predictive scoring system was developed based on the coefficients from the multivariate analysis. The point assignment for each predictor was determined by rounding the absolute values of their multivariate logistic regression coefficients to the nearest integer. Time from diagnosis to surgery >3 months was assigned 2 points, blunt occlusion morphology was assigned 1 point, occlusion length > 30 mm was assigned 2 points, and absence or insufficiency of distal collateral compensation was assigned 1 point. The total score for each patient ranged from 0 to 6 points. A receiver operating characteristic (ROC) curve was generated using this scoring system (Figure 1). The Youden index was calculated to be 0.568, and the area under the curve (AUC) was 0.817 (95% CI: 0.698–0.936, p < 0.001). The optimal cutoff score was 2.5 points. Patients with a score of 0–2 had a higher likelihood of successful recanalization, with a sensitivity of 0.714 and specificity of 0.854.
Figure 1
3.4 Example case
An 84-year-old female presented with speech impairment for 4 days, which worsened with dysphagia over the last 2 days (0 points for symptoms). CTA and DSA indicated proximal and mid-basilar artery occlusion (Figures 2A,B), with a blunt stump morphology (1 point) (Figures 2A,B, red arrow), and good collateral compensation to the distal occlusion site (0 points). The occlusion length was <30 mm (0 points), resulting in a total lesion score of 1 point. Based on the scoring system, the patient had a high likelihood of successful endovascular recanalization (Figure 2C).
Figure 2
4 Discussion
Recent studies indicate that non-acute occlusions of large intracranial arteries are more prevalent among Asians, Hispanics, and African Americans (20). BAO occurs in approximately 1.2–2.5% of strokes, making it the most common site of posterior circulation vascular occlusion (21–23). Currently, there are no established domestic or international guidelines for the EVTof NABAO. Symptomatic intracranial artery occlusion carries an annual stroke risk of up to 23.4% (24, 25). A non-randomized controlled study on posterior circulation bypass surgery demonstrated positive outcomes; however, surgical revascularization of the posterior circulation is more challenging than that of the anterior circulation, necessitating experienced centers and surgeons. Additionally, the study had a limited sample size (with only 12 BAO patients enrolled) (26). Consequently, this procedure has not been widely adopted. The evolution of EVT for ABAO has been shaped by conflicting evidence from early and recent clinical trials. Early randomized controlled trials (RCTs), such as the Endovascular Treatment versus Standard Medical Treatment for Basilar Artery Occlusion (BEST) trial and the Basilar Artery International Cooperation Study (BASICS), did not demonstrate the superiority of EVT combined with BMT despite numerical trends favoring thrombectomy (22, 27). Indeed, the high crossover rate in the BEST trial and the lack of continuous enrollment in BASICS limited the certainty of their results. Recent RCTs, such as ATTENTION and BAOCHE, focused on patients with moderate-to-severe neurological deficits (NIHSS ≥10) and extended the treatment time window to 24 h. These trials clearly demonstrated the significant advantages of EVT: the ATTENTION trial (46% vs. 23%) and the BAOCHE trial (46% vs. 24%) found that the proportion of patients achieving a mRS score of 0–3 at 90 days was significantly higher in the EVT group compared to the BMT group for acute BAO patients within 12 h and 6–24 h from symptom onset, respectively (18, 28). Finally, a meta-analysis of the aforementioned four studies revealed that, for stroke patients treated within 12 h of onset, endovascular therapy significantly improved rates of favorable functional recovery (45% vs. 30%) and functional independence (35% vs. 21%) at 90 days, reduced mortality (36% vs. 45%) and overall disability severity, but increased the risk of symptomatic intracranial hemorrhage (5% vs. <1%) compared to the control group. Additionally, treatment benefits were more pronounced in patients with baseline NIHSS ≥10 and those with proximal vascular occlusions (9). These findings align with the updated European Stroke Organization (ESO) guidelines recommending EVT + BMT for BAO within 24 h in eligible patients, emphasizing the critical role of time-sensitive, imaging-guided decision-making (10). Its efficacy is comparable to that of EVT for anterior circulation large vessel occlusions, providing new evidence-based support for the treatment of basilar artery occlusion.
Li et al. retrospectively analyzed 18 patients with non-acute dominant vertebrobasilar artery occlusion and compared them with 32 patients with acute atherosclerotic vertebrobasilar artery occlusion undergoing EVT (29). Successful recanalization was achieved in 16 cases (88.9%) of non-acute occlusion and 30 cases (93.8%) of acute occlusion (p = 0.948), indicating no significant difference between the groups. Furthermore, the modified Rankin Scale (mRS) scores at 90 days post-procedure were comparable, suggesting that EVT for non-acute occlusion yields similar clinical outcomes and success rates as for acute occlusion.
However, recanalization of basilar artery occlusions remains technically challenging due to variations in occlusion length and access vessel curvature. Complications at the occlusion site, such as hemorrhage and vascular dissection, can lead to catastrophic outcomes. Therefore, comprehensive preoperative evaluation, particularly of lesion characteristics, is essential for predicting recanalization success and aiding operators in assessing the feasibility of occlusion reopening.
4.1 Occlusion time and technical success rate
Previous studies suggest that EVT within three months of occlusion onset may be feasible for patients with intracranial artery occlusion (30, 31). The success rate of vascular recanalization decreases as the duration of occlusion increases due to thrombus organization and fibrosis, leading to calcified plaque formation and increased difficulty in traversing the occlusion with microguidewires (32). Currently, there is no consensus on the optimal timing for EVT in NABAO, and further multicenter randomized studies are needed to provide high-quality evidence. Our findings also suggest that a longer duration of occlusion is associated with a lower likelihood of successful recanalization.
4.2 Vascular occlusion residual end morphology and length
A multicenter retrospective study on EVT for symptomatic non-acute extracranial vertebral artery occlusion indicated that the morphology of the occlusion stump is associated with recanalization difficulty (33). A tapered (conical) stump facilitates smoother guidewire passage through the occlusion, whereas a blunt stump decreases the success rate of guidewire traversal. Our study also highlighted that occlusions longer than 30 mm have lower success rates, possibly due to increased difficulty in guidewire navigation and a higher risk of vessel wall injury. These findings suggest that both longer lesion length and blunt occlusion morphology are negative predictors for successful EVT recanalization. Such information is valuable in preoperative patient selection, helping to identify those who are more likely to benefit from EVT.
4.3 Collateral circulation and distal occlusion condition
Our study also indicated that the condition of the distal end of the occlusion plays a critical role in EVT. Visualization of the distal vessel via retrograde perfusion provides a target for guidewire navigation, facilitating accurate traversal of the occlusion and reducing procedural difficulty. Previous studies have identified poor collateral circulation as a risk factor for hyperperfusion syndrome (34), while robust collateral networks may decrease the incidence of hyperperfusion injury. Additionally, good collateral circulation is associated with higher recanalization success rates (35). Our findings are consistent with previous studies, and these factors play a crucial role in informing our preoperative evaluations.
Based on our statistical findings, we developed a scoring system to identify patients who are most likely to benefit from EVT recanalization. This tool aids in patient selection by quantifying negative predictors, thereby avoiding unnecessary risks in patients with a lower likelihood of procedural success and guiding alternative treatment strategies for them. In clinical practice, clinicians can assign scores to patients based on four readily assessable parameters (occlusion duration, morphology, length, and collateral compensation). Patients with a score ≤ 2 points (e.g., occlusion duration ≤3 months, tapered stump, length ≤ 30 mm, good collaterals) have an over 80% probability of successful recanalization, justifying the treatment. On the other hand, patients with a score > 2 points may require careful consideration. However, since this model was developed using historical data, it may overestimate performance in real-world settings due to selection bias. Additionally, this scoring system does not account for intraoperative factors (e.g., operator experience). Future studies are expected to refine the scoring criteria by integrating high-resolution vessel wall imaging (HR-VWI) and perform external validation in geographically diverse cohorts (e.g., European and North American centers) to assess its generalizability across populations with varying occlusion etiologies and treatment protocols.
This study has several limitations. Due to the retrospective multicenter design and the lack of high-resolution vessel wall imaging (HR-VWI) data, our ability to explore these vessel wall characteristics as potential predictors is limited. Additionally, the retrospective nature of this study may introduce selection bias, and there is a lack of long-term follow-up data. Future prospective studies should expand the sample size, integrate HR-VWI to validate the findings and refine the predictive model, and extend follow-up duration to assess long-term clinical outcomes.
5 Conclusion
This study identifies several independent negative predictors of successful recanalization in EVT for NABAO. These predictors include a time interval from diagnosis to surgery greater than 3 months, blunt occlusion stump morphology, an occlusion length exceeding 30 mm, and insufficient or absent distal collateral compensation. Recognizing these factors is critical in preoperative patient selection and may help clinicians optimize treatment strategies by identifying those patients most likely to benefit from endovascular intervention while considering alternative approaches for those with a lower likelihood of success.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by the Medical Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants' legal guardians/next of kin due to the retrospective nature of this study.
Author contributions
YL: Conceptualization, Data curation, Formal analysis, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. ZW: Conceptualization, Data curation, Formal analysis, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. SW: Conceptualization, Data curation, Formal analysis, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. WH: Conceptualization, Data curation, Writing – review & editing. WY: Conceptualization, Data curation, Writing – review & editing. SX: Conceptualization, Methodology, Writing – review & editing. BH: Conceptualization, Methodology, Writing – review & editing. CQ: Conceptualization, Funding acquisition, Supervision, Writing – review & editing. WG: Conceptualization, Funding acquisition, Methodology, Supervision, Validation, Writing – review & editing. ZY: Conceptualization, Funding acquisition, Methodology, Supervision, Validation, Writing – review & editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. The research leading to these results received funding from Joint Project on Regional High-Incidence Diseases Research of Guangxi Natural Science Foundation under Grant No. 2024GXNSFAA010221, National Nature and Science Foundation of China under Grant Agreement Nos. 82360456, 82060226, and 82260240, Guangxi Nature and Science Foundation under Grant Agreement Nos. 2018GXNSFAA138010, and 2019GXNSFAA185029, as well as “Medical Excellent Award” funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University under Grant Agreement Nos. 201907 and 202101. These fundings play important roles in the study design, acquisition analysis and interpretation of data, as well as in drafting the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
YogendrakumarVVandelanotteSMistryEAHillMDCouttsSBNogueiraRGet al. Emerging adjuvant thrombolytic therapies for acute ischemic stroke reperfusion. Stroke. (2024) 55:2536–46. doi: 10.1161/strokeaha.124.045755
2.
LuKNiWYueJChengYDuJLiYet al. Flow cytometry-based peripheral blood analysis as an easily friendly tool for prognostic monitoring of acute ischemic stroke: a multicenter study. Front Immunol. (2024) 15:1402724. doi: 10.3389/fimmu.2024.1402724
3.
KimJHongUYoonCWBaeJWRhaJHParkHK. Pcsk 9 inhibitor in acute ischemic stroke patient receiving mechanical Thrombectomy: early outcomes and safety. Front Neurol. (2024) 15:1375609. doi: 10.3389/fneur.2024.1375609
4.
XuHLiHZhangPGaoYLiuHShenHet al. Reperfusion status and postoperative blood pressure in acute stroke patients after endovascular treatment. Front Neurol. (2023) 14:1238653. doi: 10.3389/fneur.2023.1238653
5.
ZiWSongJKongWHuangJGuoCHeWet al. Tirofiban for stroke without large or medium-sized vessel occlusion. N Engl J Med. (2023) 388:2025–36. doi: 10.1056/NEJMoa2214299
6.
HuttenEMvan de VenAMenckeRPleijhuisRG. Angioedema after use of recombinant tissue-type plasminogen activators in stroke. Stroke. (2024) 55:2193–7. doi: 10.1161/strokeaha.124.047060
7.
CostalatVJovinTGAlbucherJFCognardCHenonHNouriNet al. Trial of Thrombectomy for stroke with a large infarct of unrestricted size. N Engl J Med. (2024) 390:1677–89. doi: 10.1056/NEJMoa2314063
8.
KimJOlaiyaMTDe SilvaDANorrvingBBoschJDe SousaDAet al. Global stroke statistics 2023: availability of reperfusion services around the world. Int J Stroke. (2024) 19:253–70. doi: 10.1177/17474930231210448
9.
NogueiraRGJovinTGLiuXHuWLangezaalLCMLiCet al. Endovascular therapy for acute vertebrobasilar occlusion (VERITAS): a systematic review and individual patient data meta-analysis. Lancet. (2025) 405:61–9. doi: 10.1016/S0140-6736(24)01820-8
10.
StrbianDTsivgoulisGOspelJRätySCimflovaPGeorgiopoulosGet al. European stroke organisation (ESO) and European Society for Minimally Invasive Neurological Therapy (ESMINT) guideline on acute management of basilar artery occlusion. J Neurointerv Surg. (2024) 16:e7:1–32. doi: 10.1136/jnis-2024-022053
11.
NaylorRRantnerBAncettiSde BorstGJDe CarloMHallidayAet al. Editor's choice-European Society for Vascular Surgery (Esvs) 2023 clinical practice guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg. (2023) 65:7–111. doi: 10.1016/j.ejvs.2022.04.011
12.
BathlaGAjmeraPMehtaPMBensonJCDerdeynCPLanzinoGet al. Advances in acute ischemic stroke treatment: current status and future directions. AJNR Am J Neuroradiol. (2023) 44:750–8. doi: 10.3174/ajnr.A7872
13.
GaoFHanJGuoXSunXMaNMiaoZ. Endovascular recanalization for non-acute basilar artery occlusions with progressive or recurrent ischemic symptoms: a multicenter clinical experience. J Neurointervent Surg. (2022) 14:133–7. doi: 10.1136/neurintsurg-2020-017213
14.
ZhouZLiTZhuLWuLGuanMMaZet al. Endovascular recanalization of symptomatic non-acute occlusion of the vertebrobasilar artery. Front Neurol. (2023) 14:1125244. doi: 10.3389/fneur.2023.1125244
15.
LuGWangJWangTXuXLiXSunXet al. Incidence and predictors of restenosis following successful recanalization of non-acute internal carotid artery occlusion in 252 cases. J Neurointervent Surg. (2024) 17:242–7. doi: 10.1136/jnis-2024-021553
16.
QureshiAIAbou-CheblAJovinTG. Qualification requirements for performing Neurointerventional procedures: a report of the practice guidelines Committee of the American Society of neuroimaging and the Society of Vascular and Interventional Neurology. J Neuroimag. (2008) 18:433–47. doi: 10.1111/j.1552-6569.2007.00210.x
17.
ChenKHouXZhouZLiGLiuQGuiLet al. The efficacy and safety of endovascular recanalization of occluded large cerebral arteries during the subacute phase of cerebral infarction: a case series report. Stroke Vasc Neurol. (2017) 2:124–31. doi: 10.1136/svn-2017-000086
18.
JovinTGLiCWuLWuCChenJJiangCet al. Trial of Thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion. N Engl J Med. (2022) 387:1373–84. doi: 10.1056/NEJMoa2207576
19.
ChenYHLeongWSLinMSHuangCCHungCSLiHYet al. Predictors for successful endovascular intervention in chronic carotid artery Total occlusion. JACC Cardiovasc Interv. (2016) 9:1825–32. doi: 10.1016/j.jcin.2016.06.015
20.
BarnardZRAlexanderMJ. Update in the treatment of intracranial atherosclerotic disease. Stroke Vasc Neurol. (2020) 5:59–64. doi: 10.1136/svn-2019-000279
21.
AlemsegedFNguyenTNAlverneFMLiuXSchonewilleWJNogueiraRG. Endovascular therapy for basilar artery occlusion. Stroke. (2023) 54:1127–37. doi: 10.1161/strokeaha.122.040807
22.
LangezaalLCMvan der HoevenEMont'AlverneFJAde CarvalhoJJFLimaFODippelDWJet al. Endovascular therapy for stroke due to basilar-artery occlusion. N Engl J Med. (2021) 384:1910–20. doi: 10.1056/NEJMoa2030297
23.
SchonewilleWJ. Best evidence on mechanical thrombectomy for patients with vertebrobasilar occlusion. Lancet Neurol. (2020) 19:102–3. doi: 10.1016/s1474-4422(19)30477-6
24.
YanSFengHMaLXuJCHanHJHuangHEet al. Predictors of successful endovascular recanalization in patients with symptomatic nonacute intracranial large artery occlusion. BMC Neurol. (2023) 23:376. doi: 10.1186/s12883-023-03424-y
25.
XiongYCampbellBCVSchwammLHMengXJinAParsonsMWet al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy. N Engl J Med. (2024) 391:203–12. doi: 10.1056/NEJMoa2402980
26.
YaoYDLiuAFQiuHCZhouJLiCWangQet al. Outcomes of late endovascular recanalization for symptomatic non-acute atherosclerotic intracranial large artery occlusion. Clin Neurol Neurosurg. (2019) 187:105567. doi: 10.1016/j.clineuro.2019.105567
27.
LiuXDaiQYeRZiWLiuYWangHet al. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial. Lancet Neurol. (2020) 19:115–22. doi: 10.1016/S1474-4422(19)30395-3
28.
TaoCNogueiraRGZhuYSunJHanHYuanGet al. Trial of endovascular treatment of acute basilar-artery occlusion. N Engl J Med. (2022) 387:1361–72. doi: 10.1056/NEJMoa2206317
29.
DuanHChenLShenSZhangYLiCYiZet al. Staged endovascular treatment for symptomatic occlusion originating from the intracranial vertebral arteries in the early non-acute stage. Front Neurol. (2021) 12:673367. doi: 10.3389/fneur.2021.673367
30.
LindsbergPJSairanenTNagelSSalonenOSilvennoinenHStrbianD. Recanalization treatments in basilar artery occlusion-systematic analysis. Eur Stroke J. (2016) 1:41–50. doi: 10.1177/2396987316629889
31.
ZiWQiuZWuDLiFLiuHLiuWet al. Assessment of endovascular treatment for acute basilar artery occlusion via a Nationwide prospective registry. JAMA Neurol. (2020) 77:561–73. doi: 10.1001/jamaneurol.2020.0156
32.
GaoPWangYMaYYangQSongHChenYet al. Endovascular recanalization for chronic symptomatic intracranial vertebral artery Total occlusion: experience of a single center and review of literature. J Neuroradiol. (2018) 45:295–304. doi: 10.1016/j.neurad.2017.12.023
33.
GaoFZhengHGuoXSunXMiaoZ. A novel angiographic classification for the endovascular recanalization of symptomatic nonacute extracranial vertebral artery occlusion. J Neurointervent Surg. (2022) 14:210–4. doi: 10.1136/neurintsurg-2021-017283
34.
XuSSunBZhangTWuPJiZWangCet al. Staged carotid artery stenting for prevention of hyperperfusion-induced intracerebral hemorrhage in patients with very high-grade carotid stenosis and poor collateral compensation. World Neurosurg. (2023) 171:e38–46. doi: 10.1016/j.wneu.2022.11.057
35.
LiuYTianXLeungTWLiuLLiebeskindDSLengX. Good collaterals and better outcomes after Evt for basilar artery occlusion: a systematic review and meta-analysis. Int J Stroke. (2023) 18:917–26. doi: 10.1177/17474930231154797
Summary
Keywords
non-acute basilar artery occlusion, endovascular intervention, recanalization, predictors, occlusion length, collateral compensation
Citation
Liu Y, Wu Z, Wei S, He W, Ye W, Xu S, Huang B, Qin C, Gao W and Ye Z (2025) Predictors of successful recanalization following endovascular intervention in non-acute basilar artery occlusion. Front. Neurol. 16:1496852. doi: 10.3389/fneur.2025.1496852
Received
15 September 2024
Accepted
18 March 2025
Published
07 April 2025
Volume
16 - 2025
Edited by
Robin Lemmens, University Hospitals Leuven, Belgium
Reviewed by
Ting-yu Yi, Zhangzhou Affiliated Hospital of Fujian Medical University, China
Laura Harris, Davenport University, United States
Updates
Copyright
© 2025 Liu, Wu, Wei, He, Ye, Xu, Huang, Qin, Gao and Ye.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wen Gao, gaowen0602@163.com; Ziming Ye, yeziming1620@163.com
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.